[Combination therapy with insulin and alpha-glucosidase inhibitor].
Watanabe
Kenji
K
Department of Medicine, Metabolism & Endocrinology, Juntendo University School of Medicine.
Kawamori
Ryuzo
R
D020909:Acarbose / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007294:Inositol / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D007328:Insulin / Q000008:administration & dosage*; D019518:Postprandial Period
D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D007294:Inositol; C102817:voglibose; D020909:Acarbose